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Background: Recent studies suggest the significance of right ventricular (RV) function in the outcome in patients
with left ventricular dysfunction (LVSD); however, global assessment of RV remains to be determined by
echocardiogram because of its complex geometry. This study aimed to validate RV outflow tract fractional
shortening (RVOT-FS) in the evaluation of RV function and its prognostic value in patients with LVSD.
Methods: This study included eighty-one patients (62 ± 17 years, mean ± SD, male 79%) with reduced LV ejection
fraction (LVEF) (≤40%). Two-dimensional echocardiogram of the parasternal short axis view was obtained at the
level of the aortic root, and RVOT-FS was calculated as the ratio of end-diastole minus end-systole dimension to
end-diastole dimension.
Results: RVOT-FS ranged from 0.04 to 0.8 (0.3 ± 0.2, mean ± SD), and correlated with LVEF (r = 0.33, p = 0.0028),
RV fractional area change (r = 0.37, p = 0.0008) and brain natriuretic peptide level (r = -0.38, p = 0.0005). In Cox
multivariate regression analysis, RVOT-FS [hazard ratio (HR) 0.028, 95% confidence interval (CI): 0.002-0.397];
p = 0.008] and New York Heart Association functional class III-IV [HR 2.233, 95% CI: 1.048-4.761]; p = 0.037] were
independent factors to predict the events. During a median follow-up period of 319 days (1 to 1862 days), patients with
RVOT-FS≥ 0.2 showed a higher event-free rate than those < 0.2 by Kaplan-Meier analysis (log-rank test, p = 0.0016).
Conclusions: Our data suggest that RVOT-FS is a simple parameter reflecting the severity of both ventricular function in
patients with LVSD. In addition, RVOT-FS might be useful to predict adverse outcomes in such a patient population.
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Left ventricular ejection fraction is well recognized in
the adverse clinical outcomes of patients with chronic
heart failure [1]; however, it loses statistical power when
applied to patients with advanced heart failure [2]. In
this setting, RV function determines exercise capacity
and survival [2-4]. Although several echocardiographic
parameters have been proposed [5], accurate global
assessment of the RV is still challenging because of
its complex anatomy; RV is not one chamber, but is* Correspondence: ttsuruda@med.miyazaki-u.ac.jp
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distribution, and reproduction in any mediumcomposed of two distinct anatomic units, the RV sinus
(from the tricuspid valve annulus to the proximal os
infundibulum) and right ventricular outflow tract (RVOT)
(from proximal os infundibulum to the pulmonary valve)
[6]. Regional RVOT dysfunction is suggested to affect
exercise tolerance after tetralogy of Fallot repair [7].
Thus, RVOT appears to have its own hemodynamic
characteristics by reflecting the RV sinus and pulmonary
artery [8]; however, few studies have addressed the im-
pact of RVOT function on patients with left ventricular
systolic dysfunction (LVSD). Based upon the unique
nature of anatomy, we hypothesized that contractility of
RVOT segment might be associated with the severity of
heart failure and that it affects the prognosis of patients
with LVSD. The aim of this study was to evaluatetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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boratory and echocardiographic parameters. Second, we
examined if the measurement of RVOT-FS is a useful
parameter providing predictive value in these patients.
Methods
Patients
This study included 81 patients hospitalized at Miyazaki
University Hospital between March 2007 and November
2011. Patients were selected based on the impaired LV
systolic function (LV ejection fraction (EF) <40%) but
not on clinical symptoms, and excluded if they had
LVSD due to acute myocarditis and tachycardia-induced
cardiomyopathy. Patients underwent coronary angiography,
201Tallium-/ 123I-β-methyl iodophenyl pentadecanoic acid
scintigraphy, 18fluoro-deoxyglucose by positron emission
tomography imaging, magnetic resonance imaging and
endmyocardial biopsy to aid in the definition of the etiology
of LVSD, such as ischemic heart disease, hypertensive heart
disease, valvular heart disease and secondary cardiomyopa-
thies (ex. sarcoidosis or other infiltrative cardiomyopathies).
We notified the patients in writing and on the homepage,
or gave written informed consent. This study was approved
by the Human Investigation Review Committee of the
University of Miyazaki (No.979) and conformed with
the principles outlined in the Declaration of Helsinki
(Cardiovasc Res 1997; 35: 2-4).
Echocardiography
Echocardiography was performed using an ATL Philips
IE33 Ultrasound machine (Garnerville, NY, USA) with
the determination of standard and Doppler parameters.
Echocardiographic data on admission and at the out-patient
clinic were stored (DICOM format), and reviewed digitally
off-line on a desktop computer with ProSolv software
(ProSolv Cardiovascular Analyzer 3.5; Indianapolis, IN,






Figure 1 Two-dimensional view of right ventricular outflow tract at e
pulmonary valve; TV, tricuspid valve; RA, right atrium; LA, left atrium; AV, aoatrium (LA), LV at end-diastole (LVDd) and end-systole
(LVDs), and wall thickness of the intraventricular
septum (IVSTd) and posterior wall (LVPWTd) at diastole
were determined from the two-dimensional parasternal
long-axis view on electrocardiogram. LVEF was calculated
by the modified Simpson’s method in apical four- and
two-chamber views. For evaluating the RV fractional
area change (RVFAC), endocardial borders were outlined at
end-diastole and end-systole, using an apical four-chamber
view [9], and RVFAC (%) was calculated by (RV end-
diastolic area – RV end-systolic area)/RV end-diastolic
area x100. Tricuspid regurgitation-pressure gradient
(TR-PG) was estimated by the peak continuous-wave
Doppler velocity of the tricuspid regurgitation jet using
the modified Bernoulli equation. The RVOT dimension
was measured in end-diastole and end-systole at
parasternal-short axis view at the level of the aortic
root using two-dimensional echocardiogram between 1 to
3 cardiac cycles on electrocardiogram, and RVOT-FS was
calculated as (dimension at end-diastole – end-systole)/
end-diastole (Figure 1). This was modified to the original
study by Lindqvist et al. [8] who determined the RVOT
dimension on M-mode. Each patient was asked to return
for a follow-up echocardiogram or it was performed when
they were re-admitted to the hospital.
Cine magnetic resonance imaging (cine MRI)
We validated the RVOT-FS assessed by echocardiogram
with 1.5-Tesla MRI system (Signa HDxt, GE Healthcare
UK Ltd., Buckinghamshire, United Kingdom). Nine sub-
jects were in the supine position with breath holding in
expiration and with a vector-cardiographic method for
electrocardiographic gating. Transaxial slices using the
rephrased gradient echo technique was planned to cover
the heart from a level just below of diaphragm to bronchial
bifurcation, with repetition time of 2.7-2.9 msec, echo






nd-diastole and end-systole. RVOT, right ventricular outflow tract; PV,
rtic valve.
Table 1 Patient’s characteristics
Age, years 62 ± 17
Sex Male (79%)
NYHA functional class III-IV 17 (21%)










Sinus rhythm 54 (67%)
Atrial fibrillation 19 (23%)




Calcium channel blocker 16 (20%)
Diuretic 61 (75%)
Aldosterone antagonist 47 (58%)
Laboratory test
BNP (pg/mL) 765 ± 870
Uric acid (mg/dL) 7.4 ± 2.6
Hemoglobin (g/dL) 14.0 ± 2.1
Total bilirubin (mg/dL) 1.1 ± 0.8
C-reactive protein (mg/dL) 1.5 ± 2.9
eGFR (mL/min/1.73 m2) 51 ± 20
Echocardiographic examination
LAD (cm) 4.1 ± 0.8
IVSTd (cm) 1.0 ± 0.3
LVPWTd (cm) 1.1 ± 0.3
LVDd (cm) 6.1 ± 1.0
LVDs (cm) 5.4 ± 1.1
LVEF (%) 30 ± 8
RVFAC (%) 35 ± 14
TR-PG (mmHg) 25 ± 12
Values are expressed as absolute numbers (%) or the mean ± SD.
NYHA New York Heart Association, IHD ischemic heart disease, DCM dilated
cardiomyopathy, HCM hypertrophic cardiomyopathy, HHD hypertensive heart
disease, Others include 2 sarcoidosis, 1 LV noncompaction, 1 restrictive
cardiomyopathy and 2 unknown origin, ACE-I angiotensin converting enzyme
inhibitor, ARB angiotensin II type 1 receptor antagonist, BNP brain natriuretic
peptide, eGFR estimated glomerular filtration rate, LAD left atrial dimension
(diastole), IVSd intraventricular septal wall thickness (diastole), LVPWTd left
ventricular posterior wall thickness (diastole), LVEF left ventricular ejection
fraction, RVFAC right ventricular fractional area change, TR-PG tricuspid
regurgitation-pressure gradient.
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and end-systole were measured on still frames with manual
tracing by means of a track-ball cursor.
Laboratory tests
Plasma brain natriuretic peptide (BNP) concentration
was measured by chemiluminescent immunoassay
(ARCHITECT BNP-JP; Abott, Chiba, Japan). C-reactive
protein in the serum was determined by the latex agglutin-
ation test with a measurement range of 0.01 to 32 mg/dL.
Estimated glomerular filtration rate (eGFR) was calculated
using the equation for the Modification of Diet in Renal
Disease [10].
Follow-up and end points
Follow-up was performed by direct examination of medical
records or by contact with cardiologists. All patients were
followed up until October 2012 unless a major end point
terminated the follow-up. In the present study, outcomes
were included such as death from cardiovascular diseases
(heart failure and lethal arrhythmia), requirement of
cardiac transplantation, and unexpected hospitalization
due to the worsening of heart failure [11].
Statistical analysis
Data analyses were performed using GraphPad Software
Prism 5 (GraphPad Software, San Diego, CA, USA) for
Bland-Altman plot and SPSS version 11.0 (SPSS Japan,
Tokyo, Japan) for the rest of the analyses. We used Stu-
dent’s t-test or Mann-Whitney test for two continuous
parametric or nonparametric variables, and the Fisher’s
exact test for qualitative data such as numbers and per-
centages. Unadjusted and adjusted associations of
RVOT-FS with other clinical parameters were evalu-
ated by Spearman rank-correlation coefficient and multi-
variate linear regression. There were close relationships
between the following two variables [LVDd and LVDs (r =
0.886, p < 0.0001)] and [IVSTd and LVPWTd (r = 0.650, p
< 0.0001)], and we removed LVDs and LVPWTd as vari-
ables in the analysis. A Cox proportional hazards model
was used to determine any variables as significant factors to
predict cardiovascular events in the study subjects. The
covariates included in this model were age, sex, use of
β-blocker, angiotensin converting enzyme inhibitor (ACE-
I) /angiotensin II type 1 receptor antagonist (ARB), cal-
cium channel blocker, diuretic and aldosterone antag-
onist, rhythm in electrocardiogram, echocardiographic
parameters (LAD, IVSTd, LVDd, LVEF, RVFAC, RVOT-
FS, TR-PG), BNP, eGFR, hemoglobin, total bilirubin, uric
acid, C-reactive protein and New York Heart Association
(NYHA) functional class. Results are presented as relative
risk with 95% confident interval (CI). Kaplan-Meier analysis
was constructed by receiver operating characteristics
(ROC) analysis. In addition, Bland-Altman plots were used














Uric acid -0.28 0.0116
Total bilirubin -0.30 0.0061
C-reactive protein -0.29 0.0092
eGFR 0.20 0.086
NYHA New York Heart Association, LAD left atrial dimension (diastole), IVSTd
intraventricular septal wall thickness (diastole), LVPWTd left ventricular
posterior wall thickness (diastole), LVDd left ventricular end-diastolic
dimension, LVDs left ventricular end-systolic dimension, LVEF left ventricular
ejection fraction, RVFAC right ventricular fractional area change, TR-PG
tricuspid regurgitation-pressure gradient, BNP brain natriuretic peptide, eGFR
estimated glomerular filtration rate.
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diography vs. cine MRI). The plot was displayed as the
average of the two values and the difference between the
two measurements. Results are shown as absolute numbers
(%) or the mean ± standard deviation (SD). Statistical sig-
nificance was accepted when p < 0.05.
Results
Patients’ characteristics
Table 1 summarizes clinical characteristics and echocar-
diographic variables of the 81 patients enrolled in this
study. Etiology of LVSD was heterogeneous, and 23% ofFigure 2 Plasma BNP level (A) and RVOT-FS (B), according to NYHA fu
functional class were I 31; II 33; III 15; IV 2.them exhibited atrial fibrillation, and mean value of
LVEF was 30%.
Spectrum of RVOT-FS
RVOT diameter was 3.1 cm at end-diastole (range,
1.9-5.3 cm) and 2.1 cm at end-systole (range, 0.4-4.5 cm),
and the mean value of RVOT-FS was 0.3 (range, 0.04-0.8).
Table 2 summarizes that RVOT-FS was associated with
NYHA functional class III-IV (r = -0.27), LAD (r = -0.45),
LVDd (r = -0.29), LVDs (r = -0.32), LVEF (r = 0.33), RVFAC
(r = 0.37), BNP (r = -0.38), uric acid (r = -0.28), total
bilirubin (r = -0.30), or C-reactive protein (r = -0.29),
but not with age, IVSTd, LVPWTd, TR-PG or eGFR.
Figure 2 shows that plasma BNP level increased (A),
whereas RVOT-FS decreased (B), according to NHYA
functional class. As shown in Table 3, RVOT-FS was
independently associated with BNP and LVDd.
Clinical characteristics of patients with or without
cardiovascular event
During a median follow-up period of 319 days (1 to
1862 days), all-cause events occurred in 38 patients
(cardiac death, 13; requirement of cardiac transplantation,
2; unexpected hospitalization due to the worsening of
heart failure, 23). Table 4 summarizes that patients who
had an event were older, with higher BNP and total biliru-
bin level, and a greater prevalence of diuretic use. On the
other hand, they showed a lower concentration of eGFR.
On the echocardiogram, LAD was significantly increased,
whereas RVOT-FS and IVSTd were decreased in the event
group. LVEF, RVFAC or TR-PG did not change between
the two groups.
Univariate and multivariate Cox regression analyses
Table 5 summarizes the univariate and multivariate Cox
regression analyses using forward step-wise variable
selection. In univariate regression analysis, RVOT-FS,
NYHA functional class III-IV, IVSTd, diuretic use, BNP
and total bilirubin were extracted as significant factorsnctional class in LVSD patients. Number of patients in NYHA






RVOT-FS BNP -0.415 0.001
LVDd -0.324 0.005
Age, NYHA functional class, LAD, IVSTd, LVDd, LVEF, RVFAC, TR-PG, total
bilirubin, uric acid, BNP, C-reactive protein and eGFR were included as
independent variables.
Table 4 Clinical characteristics and echocardiographic
variables of patients with or without cardiovascular event
Parameters (-) (n = 43)
Cardiovascular event
(+) (n = 38) p value
Age 58 ± 17 66 ± 15 0.037 1)
Male 36 28 0.289 2)
NYHA functional class III-IV 6 12 0.067 2)
IHD 10 10 0.800 2)
Rhythm (Af / pacing) 10 17 0.059 2)
BNP (pg/mL) 580 ± 805 965 ± 903 0.005 3)
Total bilirubin (mg/dL) 0.93 ± 0.53 1.34 ± 0.98 0.018 1)
Uric acid (mg/dL) 7.08 ± 1.89 7.76 ± 3.18 0.235 1)
eGFR (mL/min/1.73 m2) 55.8 ± 18.9 44.9 ± 19.8 0.015 1)
Hemoglobin (g/dL) 14.3 ± 2.3 13.5 ± 1.9 0.081 1)
C-reactive protein (mg/dL) 1.4 ± 3.0 1.5 ± 2.9 0.039 3)
LAD (cm) 3.89 ± 0.66 4.43 ± 0.91 0.003 1)
IVSTd (cm) 1.08 ± 0.35 0.87 ± 0.24 0.004 1)
LVPWTd (cm) 1.11 ± 0.27 1.01 ± 0.21 0.070 1)
LVDd (cm) 6.06 ± 0.79 6.22 ± 1.25 0.465 1)
LVDs (cm) 5.28 ± 0.85 5.50 ± 1.28 0.356 1)
LVEF (%) 31.4 ± 7.6 28.5 ± 7.8 0.093 1)
RVOT-FS 0.38 ± 0.20 0.27 ± 0.17 0.008 1)
RVFAC (%) 38 ± 14 32 ± 14 0.086 1)
TR-PG (mmHg) 25 ± 14 25 ± 9 0.978 1)
Beta-blocker 25 29 0.102 2)
ACE-I/ARB 28 30 0.219 2)
Calcium channel blocker 11 6 0.413 2)
Diuretic 24 36 <0.0001 2)
Aldosterone antagonist 21 25 0.177 2)
Values are expressed as absolute number or the mean ± SD. Each variable was
analyzed by 1) unpaired t-test, 2) Fisher's exact test and 3) Mann-Whitney test.
NYHA New York Heart Association, IHD ischemic heart disease, Af atrial fibrillation,
BNP brain natriuretic peptide, eGFR estimated glomerular filtration rate, LA left
atrial dimension (diastole), IVSTd intraventricular septal wall thickness (diastole),
LVPWTd left ventricular posterior wall thickness (diastole), LVDd left ventricular
end-diastolic dimension, LVDs left ventricular end-systolic dimension, LVEF left
ventricular ejection fraction, RVFAC right ventricular fractional area change, TR-PG
tricuspid regurgitation-pressure gradient, ACE-I angiotensin converting enzyme
inhibitor, ARB angiotensin II type 1 receptor antagonist.
Table 5 Univariate and multivariate Cox regression
analyses
Univariate analysis Multivariate analysis
Variables HR 95% CI p value HR 95% CI p value




2.828 1.380-5.793 0.004 2.233 1.048-4.761 0.037
IVSTd 0.112 0.030-0.415 0.001
Diuretic use 6.872 1.654-28.548 0.008
BNP 1.000 1.000-1.001 0.018
Total bilirubin 1.675 1.217-2.306 0.002
Univariate and multivariate Cox regression analyses were constructed with
forward step-wise variable selection. HR hazard ratio, CI confidence interval.
Covariates included age (year), sex (male, 1; female, 2); NYHA functional class
III-IV (0, I-II; 1, III-IV); sinus rhythm in electrocardiogram (no, 0; yes, 1); BNP
(pg/mL), eGFR (mL/min/1.73 m2), hemoglobin (g/dL), total bilirubin (mg/dL), uric
acid (mg/dL) and C-reactive protein (mg/dL), echocardiographic parameters such
as LAD (cm), IVSTd (cm), LVDd (cm), LVEF (%), RVFAC (%), RVOT-FS, TR-PG
(mmHg); use (no, 0; yes, 1) of beta-blocker, ACE-I/ARB, calcium channel blocker,
diuretic and aldosterone antagonist.
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regression analysis, RVOT-FS and NYHA functional
class III-IV remained independent factors. Based on the
ROC analysis with sensitivity of 86% and specificity of 47%
(Figure 3A), we divided the patients into RVOT-FS > 0.2
or < 0.2. As shown in Figure 3B, RVOT-FS > 0.2 had a
higher prevalence of event-free periods, compared
with < 0.2 (log-rank test p = 0.0016).
Reproducibility, and validation of RVOT-FS with cine MRI
Reproducibility of the RVOT-FS measurement was evalu-
ated by calculating the intra- and inter-observer variability
in 20 patients. The intra- and inter-observer coefficient
variables were 2.5 and 14.7, respectively. We also carried
out cine MRI for nine subjects to examine the validity of
RVOT-FS assessed by echocardiogram. The Bland-Altman
plots demonstrated no evidence of substantial fixed or
proportional bias in the two methods (Figure 4).
Discussion
Assessment of RV function is important to understand
the pathophysiology of heart failure; however, it is still
challenging to find a simple and comprehensive parameter
by echocardiogram. In this study, we demonstrated that
RVOT-FS reflects the severity of both left- and right-sided
ventricular function. In addition, our data suggested
that RVOT-FS might be a useful parameter to predict
cardiovascular events in patients with LVSD.
RV originates from a different embryological source to
LV [12]. RVOT is defined as a region between the
sub-pulmonary infundibulm and pulmonary valve, and is
distinct from the rest of RV in origin and anatomy [5,6,8].
The measurement of RVOT has not been standardized in
















Figure 3 A, Receiver operating characteristics (ROC) analysis and B, Kaplan-Meier analysis to evaluate the cardiovascular event-free
rate according to the RVOT-FS in LVSD patients. AUC, area under the curve.
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[13]. In this study, patients with LVSD exhibited a rela-
tively enlarged diastolic dimension of RVOT along with its
reduced contractility. The pathophysiological and clinical
relevance of RVOT-FS measurement was not completely
elucidated in this study; however, several potential mecha-
nisms can be suggested. Original study by Lindqvist et al.
[8] showed that RVOT-FS correlated with several RV func-
tional parameters, and our data support that RVOT-FS
positively correlated with RVFAC. There are few reports
to demonstrate the RVOT-FS with clinical, laboratory and
echocardiographic variables, and our data indicate the
unique characteristics of this value. Positive correlation
with total bilirubin concentration is likely to reflect the
increased central venous pressure by the impaired RV
hemodynamics [14], and inverse correlation with serum
concentrations of uric acid [15] and C-reactive protein
[16], in part by indirectly reflecting the chronic systemic
inflammation, oxidative stress and diuretic use. It is of
note that RVOT-FS was also associated with chamber size
of LA and LV, and LVEF. We found that RVOT-FS isFigure 4 Bland-Altman plots of RVOT-FS measurement
between echocardiography and cine MRI to determine the
substantial variability of fixed or proportional bias. The 95%
limits of agreement are shown as two dotted lines.associated with LV end-diastolic dimension and BNP in-
dependently, suggesting that the magnitude of RVOT-FS
reflects the structural and functional capacity of LV as well
as RV [17,18]. The continuity of superficial muscle fibers
encircle RV and LV represents the traction of both ven-
tricular free walls, and makes up the anatomic basis for
mechanical ventricular-ventricular interaction [19,20]. LV
hemodynamic behavior was reported to be indirectly
assessed by the motion of aortic root [21], and our data
implicate that LV overload influences the motion of
RVOT. In other point of view, we speculate that the
regional contractility of RVOT may affect the LV stroke
volume if LV function have failed, because the RVOT seg-
ment contributes to up to 15% of total RV stroke volume
[6], but need further investigation. In line with previous
reports [14,22-25], cardiovascular events occurred in pa-
tients who were older, with the increased LA size, BNP
and total bilirubin concentration, and frequent diuretic
use. Interestingly, the prevalence of events was greater in
patients with decreased RVOT-FS than LVEF, TR-PG or
RVFAC. A number of factors contribute to the outcome
in patients with advanced heart failure. In this study, diur-
etic use, BNP and total bilirubin, LV wall thickness as well
as RVOT-FS and NYHA functional class was extracted as
the predictors of follow-up patients by Univariate Cox
regression analysis. LV overload is initially compensated
by the adequate increase of wall thickness, and our data
support that the reduced LV wall thickness exhibited poor
outcome, and it appears to be a consequence of maladap-
tive LV remodeling resulting from myocyte cell loss [26].
Multivariate Cox regression analysis demonstrated that
RVOT-FS as well as the severity of heart failure was an
independent prognostic value, and we showed that
RVOT-FS <0.2 exhibited poorer prognosis. However,
the specificity of cut-off value chosen by ROC curve
was low, and this might have been due to the wide
distribution of RVOT-FS in patients with NYHA
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gram, we observed that deterioration of RVOT-FS with
a minimal change in LVEF resulted in a poor outcome
(data not shown). Drighil et al. [13] reported that
RVOT-FS improved more rapidly than other RV functional
parameters such as RVFAC or tricuspid annular plane
systolic excursion after mitral valve commissurotomy.
Thus, sequential assessment of RVOT-FS by echocardio-
gram might lead to a more accurate diagnosis and would
help to determine the medical approach. Furthermore,
it would be interesting whether the intervention of any
specific pharmacotherapy and medical device to improve
the cardiovascular mortality/morbidity are associated with
the contractility of RVOT.
Study limitation
This is a retrospective observation study with a small
number of heterogeneous pathologies in patients with
LVSD. We did not assess the other RV systolic parameters,
such as peak systolic tricuspid annular velocity, integral of
the systolic wave, and tricuspid annular plane systolic
excursion [27]. In addition, we understand that an oblique
section of echocardiographic imaging at the level of RVOT
leads to underestimation of the value. Moreover, this study
included 23% patients with atrial fibrillation, and single
measurement of RVOT-FS potentially hampers the accur-
ate value. We validated the value with cine MRI, but we
agree that the reproducibility was sub-optimal [28], and it
is necessary to improve it by newer technologies [20].
Conclusion
The present study suggests that RVOT-FS is a parameter
to assess the severity of both ventricular functions in
LVSD patients. In addition, our findings implicate a
measurement of RVOT-FS might provide a predictive
value in such a patient population.
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